Tudor Investment Corp ET AL Makes New $847,000 Investment in Disc Medicine, Inc. (NASDAQ:IRON)

Tudor Investment Corp ET AL bought a new stake in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 13,353 shares of the company's stock, valued at approximately $847,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Tower Research Capital LLC TRC raised its position in Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock valued at $52,000 after purchasing an additional 266 shares during the last quarter. Teacher Retirement System of Texas lifted its position in Disc Medicine by 8.9% during the 4th quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock worth $308,000 after buying an additional 396 shares in the last quarter. Sterling Capital Management LLC grew its holdings in Disc Medicine by 798.4% during the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock worth $36,000 after acquiring an additional 503 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Disc Medicine by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company's stock valued at $400,000 after acquiring an additional 593 shares in the last quarter. Finally, MetLife Investment Management LLC raised its stake in shares of Disc Medicine by 6.6% in the fourth quarter. MetLife Investment Management LLC now owns 12,132 shares of the company's stock worth $769,000 after acquiring an additional 755 shares during the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

Disc Medicine Price Performance

Disc Medicine stock opened at $42.71 on Wednesday. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -10.73 and a beta of 0.77. The company's 50 day simple moving average is $47.60 and its 200 day simple moving average is $55.03. Disc Medicine, Inc. has a fifty-two week low of $28.25 and a fifty-two week high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.08. As a group, analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and issued a $118.00 price objective on shares of Disc Medicine in a research report on Tuesday, January 21st. Scotiabank upped their price target on Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, March 3rd. Stifel Nicolaus lifted their price objective on Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, January 24th. Cantor Fitzgerald boosted their price objective on Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a report on Tuesday, March 18th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Friday, March 7th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Disc Medicine presently has an average rating of "Buy" and a consensus target price of $93.80.

Insider Buying and Selling at Disc Medicine

In related news, insider William Jacob Savage sold 2,100 shares of the business's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $50.17, for a total value of $105,357.00. Following the sale, the insider now directly owns 66,398 shares of the company's stock, valued at approximately $3,331,187.66. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Jonathan Yen-Wen Yu sold 1,610 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $87,873.80. Following the transaction, the chief operating officer now owns 40,555 shares of the company's stock, valued at approximately $2,213,491.90. This trade represents a 3.82 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 356,290 shares of company stock valued at $19,336,901. Company insiders own 4.24% of the company's stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Want to see what other hedge funds are holding IRON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Disc Medicine, Inc. (NASDAQ:IRON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.